Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery
Authors:
- Franciele Aline BruinsmannFranciele Aline Bruinsmann
- Stefania PiganaStefania Pigana
- Tanira AguirreTanira Aguirre
- Gabriele Dadalt SoutoGabriele Dadalt Souto
- Gabriela Garrastazu PereiraGabriela Garrastazu Pereira
- Annalisa BiancheraAnnalisa Bianchera
- Laura Tiozzo FasioloLaura Tiozzo Fasiolo
- Gaia ColomboGaia Colombo
- Magno MarquesMagno Marques
- Adriana Raffin PohlmannAdriana Raffin Pohlmann
- Silvia Stanisçuaski GuterresSilvia Stanisçuaski Guterres
- Fabio SonvicoFabio Sonvico
Open Access
- 18 February 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (2) , 86
Abstract
Drug delivery to the brain represents a challenge, especially in the therapy of central nervous system malignancies. Simvastatin (SVT), as with other statins, has shown potential anticancer properties that are difficult to exploit in the central nervous system (CNS). In the present work the physico–chemical, mucoadhesive, and permeability-enhancing properties of simvastatin-loaded poly-ε-caprolactone nanocapsules coated with chitosan for nose-to-brain administration were investigated. Lipid-core nanocapsules coated with chitosan (LNCchit) of different molecular weight (MW) were prepared by a novel one-pot technique, and characterized for particle size, surface charge, particle number density, morphology, drug encapsulation efficiency, interaction between surface nanocapsules with mucin, drug release, and permeability across two nasal mucosa models. Results show that all formulations presented adequate particle sizes (below 220 nm), positive surface charge, narrow droplet size distribution (PDI < 0.2), and high encapsulation efficiency. Nanocapsules presented controlled drug release and mucoadhesive properties that are dependent on the MW of the coating chitosan. The results of permeation across the RPMI 2650 human nasal cell line evidenced that LNCchit increased the permeation of SVT. In particular, the amount of SVT that permeated after 4 hr for nanocapsules coated with low-MW chitosan, high-MW chitosan, and control SVT was 13.9 ± 0.8 μg, 9.2 ± 1.2 µg, and 1.4 ± 0.2 µg, respectively. These results were confirmed by SVT ex vivo permeation across rabbit nasal mucosa. This study highlighted the suitability of LNCchit as a promising strategy for the administration of simvastatin for a nose-to-brain approach for the therapy of brain tumors.Keywords
All Related Versions
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Ciências sem Fronteiras” BOLSA PESQUISADOR VISITANTE ESPECIAL—PVE 401196/2014-3)
This publication has 81 references indexed in Scilit:
- Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptakeJournal of Controlled Release, 2013
- Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatmentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Biocompatibility of Chitosan Carriers with Application in Drug DeliveryJournal of Functional Biomaterials, 2012
- Polymeric nanoparticles for drug delivery to the central nervous systemAdvanced Drug Delivery Reviews, 2012
- Development ofin vitromodels to demonstrate the ability of PecSys®, anin situnasal gelling technology, to reduce nasal run-off and dripDrug Development and Industrial Pharmacy, 2012
- Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastomaJournal of Experimental & Clinical Cancer Research, 2011
- The Role of Statins in Cancer TherapyThe Oncologist, 2006
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Nanocapsule Technology: A ReviewCritical Reviews™ in Therapeutic Drug Carrier Systems, 2002